Market Cap: $7.46B
AP
Alkermes plc
ALKS
NASDAQUSD
Market Cap: $7.46B
Alkermes plc (Ticker: ALKS) reports promising developments in its ongoing efforts to innovate treatment for narcolepsy type 2. The company recently revealed strong results from its phase 2 Vibrance-2…
Alkermes plc has recently released promising results from its phase 2 Vibrance-2 trial for alixorexton, an oral orexin 2 receptor agonist aimed at treating adults with narcolepsy type 2. The study ind…
Alkermes plc (Ticker: ALKS) experiences notable interest from institutional investors as recent filings reveal increased stakes and positive analyst ratings. Panagora Asset Management Inc. raises its…
Alkermes plc (Ticker: ALKS) recently celebrates a crucial achievement with the US FDA granting orphan drug designation for alixorexton, a treatment designed for idiopathic hypersomnia. This rare and d…
Alkermes plc (Ticker: ALKS) is making headlines due to impressive revenue growth and optimism surrounding its innovative treatments. The company announces a remarkable 28.2% revenue increase for the q…
In the past few days, Alkermes plc (Ticker: ALKS) showcases its commitment to advancing psychiatry treatments with the recent presentation of new clinical and real-world data surrounding its psychiatr…
Alkermes plc announces a significant development in its research pipeline with the launch of the Brilliance phase 3 program, which targets narcolepsy treatment through its oral orexin 2 receptor agoni…
Alkermes plc: Navigating Diverse Analyst Perspectives in Biopharmaceutical Innovation In the current landscape of the biopharmaceutical industry, Alkermes plc faces a complex interplay of opinions. Re…
Alkermes Highlights Commitment to Innovation Amid Strong Q4 Performance Alkermes plc announces substantial achievements in its recent quarterly earnings, signaling a robust trajectory in the biotechno…
Alkermes Demonstrates Strong Financial Performance and Commitment to Innovation Alkermes plc, a notable player in the biotechnology sector, exhibits impressive financial metrics in its latest quarterl…
Alkermes plc Faces Scrutiny in Recent Investment Analysis In a recent segment on "Mad Money," investment expert Jim Cramer provides a critical overview of various companies, including Alkermes plc, a…
Alkermes Expands Portfolio with Enhanced Offer for Avadel Pharmaceuticals Alkermes plc has recently increased its offer to acquire Avadel Pharmaceuticals plc, presenting a total transaction value of u…
Alkermes Strengthens Position in Pharma Sector with Avadel Acquisition Bid Alkermes plc has made waves in the pharmaceutical industry with its increased offer to acquire Avadel Pharmaceuticals plc for…
Alkermes Responds to Avadel Pharmaceuticals' Acquisition Offer from Lundbeck On November 14, 2025, Alkermes plc publicly acknowledges Avadel Pharmaceuticals plc's receipt of a potential acquisition of…
Alkermes Advances Treatment Options in Mental Health Alkermes plc announces significant progress in its commitment to developing innovative therapies for mental health disorders, particularly focusing…
Alkermes plc Navigates a Complex Pharmaceutical Landscape Alkermes plc finds itself in a landscape characterized by diverse analyst opinions regarding its future in the pharmaceutical industry. Over t…
Alkermes Enhances Portfolio with Avadel Pharmaceuticals Acquisition Alkermes plc, a key player in the pharmaceutical industry, announces its strategic agreement to acquire Avadel Pharmaceuticals plc f…
Alkermes Expands Its Portfolio with Strategic Acquisition of Avadel Pharmaceuticals Alkermes plc announces its agreement to acquire Avadel Pharmaceuticals plc, marking a significant strategic move in…
Alkermes plc: Navigating the Pharmaceutical Landscape Amid Tariff Changes In the current climate of tariff adjustments and the broader implications for the pharmaceutical industry, Alkermes plc stands…
Alkermes plc: Navigating Pharmaceutical Tariffs Amid Industry Changes Alkermes plc operates within a complex pharmaceutical landscape that is currently undergoing significant changes due to proposed t…
Expanding Horizons: The Growth of Psychotic Disorder Medications The psychotic disorder medication market is on the brink of significant expansion, with projections indicating a potential value of $32…
Growing Opportunities in the Psychotic Disorder Medication Market The psychotic disorder medication market is on the brink of substantial growth, with projections estimating a reach of $32.1 billion b…
Alkermes Appoints Joshua Reed as Chief Financial Officer: A Strategic Move for Growth Alkermes plc, a biopharmaceutical company specializing in innovative treatments for neurological disorders, announ…
Alkermes Champions Neuroscience Research with Pathways Awards Initiative Alkermes plc (Nasdaq: ALKS) is set to launch its eighth annual Alkermes Pathways Research Awards® program, a significant initia…
Alkermes Launches Pathways Research Awards to Support Neuroscience Innovation Alkermes plc is set to kick off its eighth annual Alkermes Pathways Research Awards® program, officially accepting applica…